Last Updated : June 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Levemir | Insulin detemir | Diabetes mellitus | Do not list | Complete | ||
| Levemir | Insulin detemir | Diabetes mellitus | Withdrawn | |||
| Levemir | Insulin detemir | Diabetes mellitus | Do not list | Complete | ||
| Levemir | Insulin detemir | Diabetes mellitus Type1, Pediatrics | Do not list | Complete | ||
| Libtayo | Cemiplimab | Advanced Cutaneous Squamous Cell Carcinoma (CSCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Libtayo | cemiplimab | Basal cell carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Libtayo | cemiplimab | Non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Libtayo | cemiplimab | Locally advanced or metastatic NSCLC (first line) | Reimburse with clinical criteria and/or conditions | Active | ||
| Livmarli | maralixibat | Alagille syndrome | Reimburse with clinical criteria and/or conditions | Active | ||
| Livtencity | maribavir | Post-transplant cytomegalovirus infection | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lixiana NVAF | Edoxaban | Nonvalvular atrial fibrillation, prevention of stroke and systemic embolism. | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lixiana VTE | Edoxaban | Venous thromboembolism, treatment and recurrence prevention. | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lodalis | Colesevelam hydrochloride | Hypercholesterolemia | Do not list at the submitted price | Complete | ||
| Lokelma | sodium zirconium cyclosilicate | Hyperkalemia, adults | Do not reimburse | Complete | ||
| Lonsurf | trifluridine and tipiracil | Metastatic colorectal cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lonsurf | Trifluridine-Tipiracil | Gastric Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lonsurf | Trifluridine and Tipiracil | Metastatic Colorectal Cancer | Do not reimburse | Complete | ||
| Lonsurf | Trifluridine and Tipiracil | mCRC Resubmission | Do not reimburse | Complete | ||
| Lorbrena | Lorlatinib | Non-Small Cell Lung Cancer (NSCLC) | Do not reimburse | Complete | ||
| Lorbrena | lorlatinib | ALK-positive locally advanced or metastatic non-small cell lung | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lotemax | Loteprednol etabonate | Post-operative inflammation following cataract surgery | Do not list | Complete | ||
| Lucentis | Ranibizumab | Myopic choroidal neovascularisation | List with criteria/condition | Complete | ||
| Lucentis | Ranibizumab | Macular degeneration, age-related | List with clinical criteria and/or conditions | Complete | ||
| Lucentis | Ranibizumab | Macular edema, diabetic | List with clinical criteria and/or conditions | Complete | ||
| Lucentis | Ranibizumab injection | Macular edema, secondary to retinal vein occlusion | List with clinical criteria and/or conditions | Complete |
Last Updated : June 30, 2024